

SATELLITE LUNCH SYMPOSIUM

You are invited!

ECR 2025 Vienna, Austria

Thursday, February 27th 12:30 – 13:30 Room N – ACV level 1

Redefining excellence in contrast-enhanced MRI: the benefits of gadopiclenol (Vueway)

Moderator: Francesco Sardanelli

Faculty

Francesco Sardanelli

Editor-in-Chief, European Radiology Experimental
Director, EuroAlM, European Network for Assessment of Imaging in
Medicine

Scientific Coordinator, Lega Italiana per la Lotta contro i Tumori (LILT) Milano Monza Brianza, Italy

Alberto Spinazzi

Chief Medical and Regulatory Officer Head, Global Medical and Regulatory Affairs, Bracco, Princeton, New Jersey, USA

Simonetta Gerevini

Direttore UOC Neuroradiologia ASST Papa Giovanni XXIII Bergamo, Italy

Guenther Schneider

Vice Chair Department of Diagnostic and Interventional Radiology, Head of MRI at Saarland University Medical Center, Homburg, Germany

General description

Gadopiclenol (Vueway) is a new, highly stable gadolinium-based contrast agent (GBCA) for MRI whose r1 relaxivity is 2-3 times higher than the r1 relaxivity values of other currently available GBCAs. It is approved in the USA and Europe for CNS and body indications at a dose of 0.05 mmol/kg bodyweight which is half that of other purely extracellular fluid GBCAs. This means that patients are exposed to half the amount of gadolinium without loss of diagnostic information, and that half the amount of gadolinium enters the environment. This symposium will focus on the safety of gadopiclenol, on its role in improving environmental sustainability and on the clinical benefits of 0.05 mmol/kg gadopiclenol specifically in MRI of the CNS and abdomen.

Safety and sustainability: evaluating the impact of reduced dose gadopiclenol.

Alberto Spinazzi

Gadopiclenol: the advantages of high relaxivity for MR imaging of the CNS.

Simonetta Gerevini

Oncologic imaging: a case view of gadopiclenol across approved indications.

Guenther Schneider

Click here to connect to "connect.myesr.org



